ImmunityBio, Inc. (IBRX)

ImmunityBio Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	56.09	14.15	-	-	0.93	0.61
Other Revenue	0.51	0.6	0.62	0.24	-	-
Revenue	56.6	14.75	0.62	0.24	0.93	0.61
Revenue Growth (YoY)	4227.22%	2270.58%	159.17%	-74.30%	54.38%	-72.52%
Gross Profit	56.41	14.75	0.62	0.24	0.93	0.61
Selling, General & Admin	157.24	173.38	135.32	108.71	126.76	61.02
Research & Development	184.54	185.55	226.67	242.2	191.6	140.26
Operating Expenses	341.77	358.93	361.99	350.91	318.36	201.28
Operating Income	-285.37	-344.18	-361.36	-350.67	-317.42	-200.67
Interest Expense	-135.58	-154.33	-129.2	-63.52	-14.85	-9.07
Interest & Investment Income	5.03	7.98	1.13	-	-	2.44
Earnings From Equity Investments	-	-	-7.55	-12.11	-0.8	-
Other Non Operating Income (Expenses)	49.42	77.52	-84.44	16.91	4.81	0.02
EBT Excluding Unusual Items	-366.51	-413.01	-581.41	-409.38	-328.27	-207.3
Merger & Restructuring Charges	-	-	-	-	-13	-10.3
Gain (Loss) on Sale of Investments	-0.63	-0.63	-1.59	-7.28	-8.72	1.47
Asset Writedown	-	-	-0.89	-0.68	-	-10.66
Other Unusual Items	0	0	-0	0.05	0.14	0.75
Pretax Income	-367.14	-413.65	-583.89	-417.29	-349.84	-226.03
Income Tax Expense	0.04	-	-0.04	0.03	0.01	-1.85
Earnings From Continuing Operations	-367.17	-413.65	-583.85	-417.32	-349.85	-224.19
Minority Interest in Earnings	0.08	0.08	0.66	0.75	3.06	2.34
Net Income	-367.09	-413.56	-583.2	-416.57	-346.79	-221.85
Net Income to Common	-367.09	-413.56	-583.2	-416.57	-346.79	-221.85
Shares Outstanding (Basic)	793	697	509	400	389	377
Shares Outstanding (Diluted)	793	700	509	400	389	377
Shares Change (YoY)	25.42%	37.71%	27.19%	2.74%	3.23%	2.93%
EPS (Basic)	-0.46	-0.59	-1.15	-1.04	-0.89	-0.59
EPS (Diluted)	-0.49	-0.62	-1.15	-1.04	-0.89	-0.59
Free Cash Flow	-356.66	-398.12	-397.34	-415.67	-307.98	-173.39
Free Cash Flow Per Share	-0.45	-0.57	-0.78	-1.04	-0.79	-0.46
Gross Margin	99.66%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-504.18%	-2334.24%	-58096.95%	-146111.67%	-33985.44%	-33169.09%
Profit Margin	-648.57%	-2804.77%	-93761.41%	-173569.58%	-37129.55%	-36669.59%
Free Cash Flow Margin	-630.15%	-2700.06%	-63881.19%	-173196.25%	-32974.52%	-28660.00%
EBITDA	-269.07	-326.63	-342.85	-332.41	-303.19	-187.93
D&A For EBITDA	16.3	17.55	18.51	18.26	14.24	12.74
EBIT	-285.37	-344.18	-361.36	-350.67	-317.42	-200.67
Revenue as Reported	56.6	14.75	0.62	0.24	-	-

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q